Illumina Tells 5th Circ. Grail Case 'Flagrant' Overreach
By Matthew Perlman · June 6, 2023, 6:53 PM EDT
Illumina told the Fifth Circuit that the Federal Trade Commission's case challenging its $8 billion repurchase of cancer testing company Grail is "flagrant" overreach that is costing lives and highlights constitutional...
To view the full article, register now.